BiondVax Pharmaceuticals Ltd. ( BVXV) Stock. Should you Buy or Sell? $ 1.05
0.03 (2.78 %)
BiondVax Pharmaceuticals Ltd. Analysis
Updated on 10-09-2022| Symbol | BVXV |
| Price | $1.05 |
| Beta | 2.355 |
| Volume Avg. | $32.84 thousand |
| Market Cap | $19.58 M |
| 52 Week Range | $0.981 - $3.49 |
BiondVax Pharmaceuticals Ltd. opened the day at $1.05 which is +'2.78 % on yesterday's close. BiondVax Pharmaceuticals Ltd. has a 52 week high of $3.49 and 52 week low of $0.981, which is a difference of $2.509. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $19.58 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy BiondVax Pharmaceuticals Ltd. for $19.58 M, it would take 15 years to get your money back. BiondVax Pharmaceuticals Ltd. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
BiondVax Pharmaceuticals Ltd. Stock Forecast - Is BiondVax Pharmaceuticals Ltd. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Strong Sell | |
| ROA Score | Sell | |
| DE Score | Strong Buy | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | -1.549 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing BiondVax Pharmaceuticals Ltd.
| Price Book Value Ratio | 14.585 | Price To Book Ratio | 14.585 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -1.549 |
How liquid is BiondVax Pharmaceuticals Ltd.
| Current Ratio | 1.706 |
| Quick Ratio | 1.706 |
Debt
| Debt Ratio | 0.948 | Debt Equity Ratio | 18.152 |
| Long Term Debt To Capitalization | 0.928 | Total Debt To Capitalization | 0.945 |
Latest news about BiondVax Pharmaceuticals Ltd.
JERUSALEM , Sept. 8, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.
JERUSALEM , May 9, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present at the 20th Biomed Israel Conference and Exhibition, to be held May 10-12, 2022, in Tel Aviv, Israel.
BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript
BVXV stock is climbing today on news that BiondVax has struck a deal to pursue a range of antibody treatments. Here's what to know.
Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) shares are trading higher by 32.1% at $1.81 after the company announced it signed a definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody therapies. BiondVax says the company is planning a rapid.
About BiondVax Pharmaceuticals Ltd.
Description :
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
